

RETINA BULLETIN

Panretinal photocoagulation in patients with proliferative diabetic retinopathy maintains a more favorable cost utility compared without intravitreal ranibizumab in patients with and without diabetic macular edema given the marginal visual benefit in intravitreal ranibizumab

“Influence of Baseline Macular Edema on Cost Evaluation of Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy”

Journal of VitreoRetinal Diseases 2019, Vol 3(5) 346-353, Sept/Oct 2019

James Lin, MD, Nicolas A. Yannuzzi, MD, Jonathan S. Chang, MD, Jayanth Sridhar, MD and William E. Smiddy, MD

For additional information and in-depth details, please visit our website, www.RVRC.com, to view the complete article.